Tumor initiation and metastasis formation in many cancers have been associated with emergence of a gene expression program normally active in embryonic or organ-specific stem cells. In particular, the stem cell transcription factor Sox2 is not only expressed in a variety of tumors, but is also required for their formation. Melanoma, the most aggressive skin tumor, derives from melanocytes that during development originate from neural crest stem cells. While neural crest stem cells do not express Sox2, expression of this transcription factor has been reported in melanoma. However, the role of Sox2 in melanoma is controversial. To study the requirement of Sox2 for melanoma formation, we therefore performed CRISPR-Cas9-mediated gene inactivation in human melanoma cells. In addition, we conditionally inactivated Sox2 in a genetically engineered mouse model, in which melanoma spontaneously develops in the context of an intact stroma and immune system. Surprisingly, in both models, loss of Sox2 did neither affect melanoma initiation, nor growth, nor metastasis formation. The lack of a tumorigenic role of Sox2 in melanoma might reflect a distinct stem cell program active in neural crest stem cells and during melanoma formation.
INTRODUCTION
The transcription factor Sox2 plays a crucial role during embryogenesis and is necessary for proper development of multiple cell types. 1, 2 It controls pluripotency in embryonic stem cells and is one of the four originally described factors required for reprogramming of differentiated cells into induced pluripotent stem cells. 3, 4 Sox2 has been extensively studied in the central nervous system, where it regulates maintenance of stem and progenitor cells. [5] [6] [7] [8] Likewise, in adult mouse tissue, Sox2 marks epithelial stem cells in various tissues of endodermal and ectodermal origin and is required for their homeostasis. 9 Moreover, conditional deletion of Sox2 impaired osteoblast proliferation and resulted in aberrant bone formation further highlighting the role of this transcription factor in a broad range of normal stem and progenitor cells. 10 Sox2 has also been implicated in controlling stem cell activity in a variety of tumors. 1 Indeed, genetic lineage tracing in medulloblastoma and squamous cell carcinoma (SCC), respectively, demonstrated that Sox2 is expressed in cancer stem cells in vivo, that is, in cells associated with tumor initiation and propagation. 11, 12 Consistent with these data, Sox2 ablation in a SCC mouse model led to decreased tumor formation. 12 More recently, Sox2 was revealed by overexpression experiments in genetically engineered mouse models to be a driver of lung SCC. 13 Sox2 was also shown to be critical for the initiation of pituitary gland tumors upon loss of the tumor suppressor p27 or of the retinoblastoma tumor suppressor gene Rb. 14, 15 Similarly, Sox2 was required for tumor initiation by murine oligodendroglioma cells and by human glioblastoma cells transplanted into appropriate mouse model systems, in agreement with the reported role of Sox2 in maintaining glioma-initiating cells. [16] [17] [18] The combined data indicate a tumorigenic role of Sox2 in many cancers. In contrast, Sox2 appears to act as a tumor suppressor gene in gastric tumors driven by canonical Wnt signal activation, pointing to context-dependent activities of Sox2 in regulating cell proliferation and tumorigenesis. 19 In melanoma, the function of Sox2 is controversial. Tissue microarray expression analysis revealed that SOX2 protein is expressed in around 50% of all human melanoma. 20, 21 In a recent study, RNAi-mediated silencing of SOX2 led to reduced melanoma sphere self-renewal and tumor growth of xenotransplanted cells, supporting an important role of Sox2 in tumor initiation and tumor maintenance. 22 In other reports, however, knockdown of SOX2 did not affect proliferation of human melanoma cells. 20, 21, 23 Instead, SOX2 knockdown cells displayed reduced invasiveness, whereas SOX2 overexpression increased the invasion capacity of human melanoma cells. 23 In agreement with this, SOX2 was recently shown to mediate TGFβ-induced invasion in human melanoma cells. 24 Thus, at least in isolated melanoma cells, SOX2 has been implicated in either growth control or invasiveness, but its function in vivo remains to be elucidated.
To shed light on this issue, we decided to analyse the role of Sox2 during melanoma oncogenesis using knockout (KO) approaches that fully block Sox2 function and, in particular, using a genetically engineered mouse melanoma model, in which metastatic melanoma spontaneously develops within an intact stromal environment. 25, 26 However, conditional Sox2 inactivation did not affect tumor initiation and progression, speaking against an essential function for this transcription factor in melanoma.
RESULTS AND DISCUSSION SOX2 expression is not linked to patient survival To address the potential relevance of SOX2 for melanoma in human patients, we first interrogated RNA sequencing (RNA-seq) and clinical data from The Cancer Genome Atlas (TCGA) and cBioPortal. 27, 28 To compare SOX2 expression levels in cutaneous melanoma with those in other cancers, we plotted the three cancers with the lowest expression (acute myeloid leukemia Figure 1 . For caption see page 4518.
Role of Sox2 in primary melanoma and metastasis formation SM Schaefer et al (AML), diffuse large B-cell lymphoma (DLBC), chromophobe renal cell carcinoma (chRCC)) and the highest expression (lung SCC, glioblastoma multiforme (GBM), lower grade (diffuse) gliomas). In addition, we analysed SOX2 expression in the three most frequently diagnosed cancers (colorectal (CRC), breast and lung cancer). Cutaneous melanoma showed low-expression levels compared to the three cancers highly expressing the transcription factor ( Figure 1a) . Next, we analysed whether SOX2 expression was changed based on the location of the biopsy or stage of the tumor, comparing primary melanoma, skin metastasis, lymph node metastasis and distant metastasis. However, we did not observe significant changes in SOX2 expression at different stages of disease progression (Figure 1b) . Breslow depth, which is defined as the total vertical height of the tumor, is one major important prognostic predictor of death from melanoma. 29, 30 Therefore, we plotted SOX2 expression from human primary melanomas to Breslow thickness. Again, we could not detect any correlation between SOX2 expression and Breslow thickness (Figure 1c) . Finally, we analysed RNA-seq-based SOX2 expression from 420 melanoma patients and established a SOX2 high (top 20%, 79 patients) and a SOX2 low (bottom 20%, 80 patients) patient group ( Figure 1d ). Interestingly, patient survival did not correlate with SOX2 expression levels, neither when considering overall survival nor when only taking expression in metastases into account (Figures 1e and f) . Taken together, SOX2 expression is not associated with clinical features and disease outcome in patients diagnosed with malignant melanoma.
SOX2 knockout does not influence tumor growth of human melanoma cells in vivo So far, a potential requirement of SOX2 for melanoma formation has been addressed using RNAi-mediated gene silencing. [20] [21] [22] [23] However, gene knockdown experiments reduce gene expression levels only partially and, furthermore, might lead to off-target effects, which could have contributed to the reported discrepancies regarding the function of SOX2 in melanoma. Therefore, we used the CRISPR-Cas9 technology to fully and genetically deplete SOX2 in human melanoma cultures. First, we tested several human melanoma cultures for SOX2 protein expression. Only one out of six cell culture analyzed (M050829, an NRas Q61L -mutated patientderived cell line), showed strong SOX2 expression, while other cell lines such as the previously used A375 and SK-MEL-28 displayed very low SOX2 protein expression (Figure 2a ). Given these results, we manipulated SOX2 levels of M050829 using the CRISPR-Cas9 genome editing technology, generating two independent SOX2 KO clones lacking SOX2 expression ( Figure 2b ). As controls, we used the original heterogeneous cell line. Strikingly, upon xenotransplantation into immunocompromised nude mice, both SOX2 KO clones displayed a growth pattern very similar to that of control melanoma cells and readily produced tumors in vivo, despite complete depletion of SOX2 (Figures 2c-e) . Thus, SOX2 was not required for melanoma formation and growth in our experimental set-up.
Sox2 is expressed in murine melanoma but not critical for survival time In many cancers other than melanoma, the undisputed role of Sox2 is in tumor initiation, potentially reflecting a 'de-differentiation' process and emergence of an embryonic gene program in cells of tumor origin. 1, 31 Conceivably, such a process cannot be adequately assessed in cell lines derived from already established metastases, such as those that have been used in previous studies of SOX2 in melanoma. Therefore, we sought to address the role of Sox2 in the Tyr::NRas Q61K Ink4a −/− mouse model that recapitulates all aspects of melanoma formation, including tumor initiation from benign melanocytic cells, primary tumor growth, dissemination of metastatic cells and secondary tumor growth at distant sites. 25, 26 First, we monitored expression of Sox2 during disease progression in mice (Figure 3a) . In normal postnatal mouse skin, Sox2 was expressed in a subset of dermal papillae, consistent with previous findings in mouse and human. 21, 32 Further, we did not detect Sox2 expression in differentiated Sox10-positive melanocytes located in hair follicle bulbs. It has been shown that~50% of human melanomas, but only a minority of nevi, express SOX2. 20, 21, 33 Likewise, Sox2 was only expressed in a small subset of Sox10-positive hyperplasia cells of Tyr::NRas Q61K Ink4a −/− mice (mean 3.2%), whereas a higher percentage of cells expressed the transcription factor in primary tumors (mean 7.9%). The percentage of Sox2/Sox10 double positive cells further increased in lymph node metastases (mean 11.2%) (Figures 3a and b) .
Based on its expression pattern, Sox2 might promote primary melanoma and metastasis formation. To address this question, we performed Tamoxifen (TM)-based activation of a melanocytespecific Cre recombinase (Tyr::Cre ERT2 ) in order to induce conditional Sox2 ablation in Tyr::NRas Q61K Ink4a −/− mice carrying two floxed alleles of Sox2 (Figure 3c ). 5 Further, we used a Cre-reporter allele (R26R::LacZ) to monitor the recombined cells in vivo. 34 Mice lacking the Tyr::Cre ERT2 transgene were used as controls. To assess if Sox2 has a role in melanoma formation, we conditionally ablated the gene before the appearance of primary melanomas by applying TM to 1-month-old animals on five consecutive days (Figure 3d ). To confirm Sox2 ablation, we co-stained three different hyperplasias for R26R::LacZ-mediated β-Galactosidase (β-Gal) and Sox2 expression. While in Sox2 conditional knockout (cKO) mice, Sox2 expression was never found in β-Gal-positive cells, the transcription factor was expressed in a subset of non-recombined, β-Gal-negative cells (Figure 3e) . Surprisingly, we did not observe a change in melanoma-specific survival between the Sox2 cKO and the control group (median survival control: 147 days, median survival Sox2 cKO: 154 days) (Figure 3f ). 44, 45 MM150423 was generated at the Department of Dermatology of the University Hospital Zurich and approved by the ethical committee of the Canton of Zurich, Switzerland. Written informed consent was obtained from all subjects and approved by the local institutional review boards (EK647 and EK800). A375, SK-MEL-28 and WM83 were purchased from ATCC. SOX2 protein expression of the human melanoma cell lines was analyzed by Western Blot (1′ antibody: sc-17320 (Santa Cruz Biotechnology, Dallas, TX, USA, 1:100); 2′ antibody: IRDye 800 CW donkey α-goat P/N 925-32214 (LI-COR, 1:10 000)). β-Actin was used as loading control (1′ antibody: 4970 (Sigma-Aldrich, St Louis, MO, USA, 1:10 000) and 2′ antibody: IRDye 680 CW donkey α-rabbit P/N 925-68072 (LI-COR, 1:10 000)). (b) Western blot analysis of SOX2 protein levels in M050829 control cell line, SOX2-CRISPR clone 1 (Cl.1) and SOX2-CRISPR clone 2 (Cl.2). Following sgRNA sequence was used for CRISPR Cl 1&2: 5′-GGCCCGCAGCAAACTTCGGGGGG-3′ with a quality score of 87 according to http://crispr.mit.edu. (c) 2-month old Foxn1 nu/nu female mice were subcutaneously engrafted with 150 000 control (black curve), SOX2 CRISPR Cl.1 (red curve), or SOX2 CRISPR Cl.2 (violet curve) cells (M050829) (n = 4 for each condition, non-blinded). Tumor volume was measured weekly with a caliper and calculated as follows: V = 2/3 × π × ((a+b)/4)), 3 where a (mm) was the length and b (mm) was the width of the tumor. One-way ANOVA analysis shows no significant difference between control cells and the two SOX2-CRISPR clones (control vs CRISPR Cl.1: P = 0.47; control vs CRISPR Cl. Sox2 is dispensable for primary tumor and metastasis formation Tyr::NRas Q61K Ink4a −/− mice reliably develop skin melanoma within 6 months of age and often present with metastases in lymph nodes, lungs and liver. 25, 26 Of note, both control as well as the Sox2 cKO mice developed a macroscopically visible hyperplasia and primary melanomas (Figures 4a and b) . Histological analysis of control and Sox2 cKO melanomas did not reveal overt changes in the morphological appearance of tumors (Figures 4a and b) .
Moreover, quantification of total skin tumor numbers failed to discriminate between the two groups ( Figure 4c ). Since in Tyr::NRas Q61K Ink4a −/− mice, TM-induced Tyr::Cre ERT2 -mediated recombination efficiency does usually not reach 100% of all melanocytic cells, primary melanoma in Sox2 cKO mice might arise from non-recombined cells. 36 To exclude this possibility, we determined the overall recombination rate (β-Galpositive/Sox10-positive cells) in hyperplastic skin and in primary tumors of Sox2 cKO mice, in which Tyr::Cre ERT2 had been activated at 1 month of age (Figure 3d) . Importantly, the percentage of recombination in skin tumors (49.0%; n = 8) was not significantly altered when compared to hyperplastic lesions (50.4%; n = 5) (Figure 4d) . Thus, loss of Sox2 neither favored nor prevented contribution of melanocytic cells to growing primary melanoma, demonstrating that Sox2 is dispensable for melanoma formation in the Tyr::NRas Q61K Ink4a −/− mouse melanoma model. It has been reported that Sox2 promotes invasiveness in cultured human melanoma cells. 23, 24 Therefore, we also analysed whether deletion of Sox2 in melanoma cells affects distant metastasis formation in vivo. However, lung and liver metastases were readily detectable in control as well as Sox2 cKO animals (Figures 4e, f, h and i) and the total count of lung and liver metastases was not significantly altered upon Sox2 deletion (Figures 4g and j) . Further, we stained lung metastases for β-Gal and Sox10 to quantify the recombination frequency of the metastasized melanoma cells. Again, when comparing the recombination frequency in hyperplastic lesions to that in lung metastases (mean 52.3%), we could not find any evidence for a positive or negative selection of Sox2 cKO cells during formation of distant metastases (Figures 4k and l) . Hence, melanocytespecific Sox2 ablation does not affect the capacity of melanoma cells to engage in metastasis formation.
In conclusion, our work suggests that the transcription factor SOX2 is not required for melanoma formation and progression. Although tissue microarray studies have previously confirmed SOX2 expression in a subset of human melanomas, 20 ,21 our analysis of TCGA data did not reveal any correlation between SOX2 levels and disease outcome. Similarly, despite its increasing expression in a fraction of melanoma cells during disease progression, Sox2 was dispensable for tumorigenesis and metastasis in a melanoma mouse model. Malignant transformation can result in gain of cellular plasticity and loss of differentiation markers. Therefore, we speculate that the upregulation of the stem cell factor SOX2 in melanoma cells compared to differentiated melanocytes might represent a bystander effect of melanoma cell transformation without major functional implications. Alternatively, the lack of phenotype in our study might be due to other Sox family members, in particular the SOX2-related factor SOX3, compensating for the absence of SOX2. 35 However, such compensation was not observed in other tumor types [11] [12] [13] [14] [15] [16] [17] [18] and we could not find evidence for SOX3 expression, neither in human SOX2 KO cells nor in murine tumors (data not shown).
Nonetheless, our findings do not rule out that SOX2 can exert certain activities in melanoma cells, for instance in isolated cells exposed to varying culture conditions or in the non-physiological environment encountered by human cells upon xenotransplantation into immunocompromised mouse model systems. 22 Of note, studies performed solely in vitro or in combination with xenotransplantation assays provided controversial results, either implicating SOX2 in melanoma cell proliferation or invasion, or also failing to reveal a crucial role in melanoma as in our experiments performed with CRISPR-Cas-mediated knockout cells. [20] [21] [22] [23] [24] While the discrepancies between our work and previously published data could potentially be explained by different experimental settings, 37 they could also reflect the heterogeneity of melanoma and, thus, leave open whether SOX2 might fulfill a role in some cases of human melanoma. However, we suggest that the pathophysiological role of Sox2 in melanoma can best be assessed in genetically engineered mouse melanoma models, in which melanoma spontaneously develops within an undisturbed stromal environment and without prior tumor cell isolation which might influence the cells' behavior. Importantly, in support of our findings obtained with Tyr::NRas Q61K Ink4a −/− mice, a parallel study performed with Tyr::CreER ; Pten l/l mice 38 also demonstrated the dispensability of Sox2 for melanoma initiation and growth. 39 Cancer formation has been associated with reactivation of embryonic or organ-specific stem cell programs. 40, 41 Accordingly, Sox2 has been functionally implicated in several tumors emerging from tissues harboring Sox2-positive stem cells. 1, 31 In melanoma, tumor-initiating cells have recently been shown to re-express markers of neural crest cells, from which melanocytes develop during embryogenesis. 42 In agreement with this −/− -driven hyperplasia. All cells expressing β-Gal (red arrowheads) lack Sox2 expression. The green arrowhead marks a Sox2-expressing pigmented cell and is β-Gal negative (scale bar, 50 μm). Three different recombined hyperplasias and three melanomas were analysed; no β-Gal/Sox2-positive cells were detected (not shown). (f) Kaplan-Meier curve comparing melanoma-specific survival after conditional Sox2 ablation (Mantel-Cox test, P = 0.96, unpaired t-test). 3-8 month old male and female mice with mixed genetic background were used. The sample size was not predetermined by statistical methods.
finding, inactivation of the neural crest stem cell factor Sox10 counteracts melanoma formation in vitro and in vivo. 25 Unlike the transcription factor Sox10, however, Sox2 is not expressed in migratory neural crest stem cells and, at early stages of development, actually suppresses neural crest induction and formation of neural crest stem cells from neural plate cells. 43 Thus, the lack of a tumorigenic function of Sox2 described in the present study is consistent with the distinct stem cell program active in neural crest stem cells and, conceivably, during melanoma formation. Role of Sox2 in primary melanoma and metastasis formation SM Schaefer et al
